GE HealthCare Buys Its Own Supply Chain and Starts Shopping Its Patient Monitoring Unit

A 6% organic quarter, a raised guide, and the first time "strategic options" has been attached to PCS — while the AI data-centre boom shows up as a cost line, not a revenue line.

GEHC · Earnings Call · 2026-10-28

A beat with a decelerating arrow buried inside it

The third quarter was unambiguously good. “Revenue of $5.5 billion increased 6.2% organically... adjusted EBIT margin of 16.6%, up 180 basis points” — William K. Grogan, CFO · 2026-10-28, adjusted EPS rose 25.1% to $1.34, free cash flow of $793 million was up $310 million year on year, and the backlog climbed 12% to $23.7 billion. Guidance was raised on the top line, on margin, on EPS and on cash. So why did the stock need to come into this print already up 19% over the last 90 trading days? Because the guide itself carries a visible deceleration. The full-year organic revenue call of "approximately 4%" against a Q3 that ran at 6.2% implies a fourth quarter in the 3–4% range. New CFO Bill Grogan was unusually direct about the cause: “the implied Q4 growth range of that 3% to 4% is really more around the PCS product hold comp versus any deceleration we see in the market” — William K. Grogan, CFO · 2026-10-28. That explanation is plausible — Q4 2025 held roughly $45 million of released product-hold revenue — and the product hold theme is a genuine recurring motif in this company's keyword history, having been the single largest mover back in 2025Q4. But the order book deserves a flag. Organic orders grew 4%, trailing-twelve-month orders 4.6%, and book-to-bill came in at 1.03x — the analyst on the call noted it as the lowest since Q1 2024. Management leaned on lumpiness and a record funnel; the funnel is not audited.

From "assessment" to "options": PCS gets a light shone on it

The most consequential sentence in the release was buried in the CEO's prepared remarks, not the numbers: “We remain focused on building on the progress the team achieved in the quarter, and we are also evaluating strategic options for this business” — Peter J. Arduini, President and CEO · 2026-10-28. That business is Patient Care Solutions, which happened to deliver its best quarter in memory — 8.8% organic growth and a 480 basis point jump in segment EBIT margin, driven by exactly the daily management and standard work disciplines the company has been preaching. That is the tell. Three months ago the same topic was still phrased as a thought experiment: “to the full extreme of, is this business better parked with someone else?” — Peter Arduini, President and Chief Executive Officer (CEO) · 2026-07-29. Now it is a formal strategic review, paired with a leadership hand-off — Jeannette Bankes departing for a public-company CEO role and internal successor Neil Sandy, who management says has been deep in the strategic assessment work. Selling into a good quarter rather than a bad one is how portfolios actually get transacted.

The AI boom as a cost line, not a revenue line

For every company claiming a piece of the AI data center buildout, there is one paying the bill. GE HealthCare is in the second camp, and it is now doing something about it. The company signed multiyear agreements with technology partners to secure supply of memory chips — an unglamorous move that reads as a hedge against a component squeeze that has already hit margins.

it is no secret that the growth of data centers and AI has a big vortex effect on certain components around the industry. We think that is gonna most likely exist for multiple years as this ramp up goes.
Peter J. Arduini, President and CEO · 2026-10-28

Note what he concedes: locking in price is not realistic, only being first in line on supply. That is a supplier's market, and the memory chips cost inflation was explicitly named by Grogan as a margin headwind alongside higher oil. This is a global consensus theme rather than a GEHC idiosyncrasy — storage and semiconductor reporters this week were still citing external component and memory cost pressure — but it lands on a medical-device P&L as pure subtraction.

What management quietly stopped saying

The absences are more interesting than the additions. Photon counting CT — the flagship of the "new wave of innovation" narrative that dominated 2025 and early 2026 — now gets one line in the prepared remarks for its CE marking, and not a single analyst question. That is a sharp inversion from April, when the same CEO was “super excited about our Photon Counting approach” — Peter Arduini, President and Chief Executive Officer · 2026-04-29 and citing a funnel north of $100 million. The innovation narrative has migrated to radiopharmaceuticals instead: SoFi Bioscience, a final-mile PET distribution asset adding roughly 1% of company revenue annualised, and the SPECT to PET conversion story around Vercado, which hit about 680 doses in the week ending October 23 and remains pointed at a $500 million run-rate exiting 2028. China is the second disappearance act. In July the language was “we feel it's prudent to continue to assume kind of a year-over-year decline in 2026” — Peter Arduini, President and Chief Executive Officer (CEO) · 2026-07-29. This quarter China grew, but the CEO was self-aware about the quality of it: “we had 7% growth in the quarter. Now albeit a majority of that was still driven by FX” — Peter J. Arduini, President and CEO · 2026-10-28. Tariffs, the margin villain of 2025, have flipped — expense down year on year, roughly $4 million of IEEPA refunds recognised, with Section 232 named as the "biggest swing item" for 2027.

The numbers behind the re-rating argument

The fundamental case is less about the quarter than about the reset in expectations. Trailing revenue of $5.3 billion grew 6% year on year, and operating margin of 14.0% is up 0.9pp — steady, not spectacular. Yet the shares trade at 14.2x trailing net income versus 25.6x at the 2024 peak. A 19% three-month rally off a de-rated base into a raised guide is a coherent sequence. The offset is leverage: effective net cash of -$8.1 billion, 24% worse year on year, as tuck-in M&A and buybacks absorb the cash. FCF conversion remains the soft spot — the free cash flow margin net of stock comp has structurally compressed over four years even as the third quarter printed strongly on collections and refund timing. The verdict: this is not a broken growth story, and it is not a re-acceleration either. It is a company using an operating-system story to buy itself time on margin, buying its own radiopharma distribution to control a bottleneck, and — most importantly — beginning the process of exiting a business that has consumed management attention for at least four quarters. The PCS review is the thing to watch; the memory chip agreements are the thing that will decide whether 2027 margins arrive on schedule.